Press releases Archives - Hamlet BioPharma

Mar

2026

Pressrelease – Lund, 15 mars 2026 – Styrelsen beslutar om justering av villkoren för teckningsoptioner av serie TO5B och inför ny kompletterande teckningsperiod 16-23 mars 2026

Hamlet Biopharma

Lund, 15 mars 2026, Hamlet BioPharma, ett innovativt läkemedelsbolag som utvecklar nya terapier mot cancer och infektioner, meddelar att styrelsen har...

Mar

2026

Nyhetsbrev – Hamlet BioPharma har undertecknat ett Letter of Intent avseende ett potentiellt kommersiellt avtal avseende Alpha 1H

Hamlet Biopharma

Newsletter, Press releases

Som tidigare meddelats har Hamlet BioPharma, tillsammans med det helägda dotterbolag Alpha1H BC AB (A1HB) och samarbetspartnern Linnane Pharma AB, und...

Mar

2026

PRESS RELEASE – Lund, March 8, 2026 – Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma AB (Hamlet), a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announces that its ...

Feb

2026

Nyhetsbrev – Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner

Hamlet Biopharma

Newsletter, Press releases

Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner Hamlet BioPharma, det innovativa ...

Feb

2026

Newsletter – Catharina Svanborg featured in Global Digital Women’s Magazine

Hamlet Biopharma

Newsletter, Press releases

Catharina Svanborg featured in Global Digital Women’s Magazine Read the interview with Hamlet BioPharma’s founder Catharina Svanborg on Femest.com, p...

Feb

2026

Q2 Interim Report October – December 2025

Hamlet Biopharma

Financial, Newsletter, Press releases

...

Feb

2026

PRESS RELEASE – Lund, February 12th, 2026 – Nature Microbiology publishes the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’

Hamlet Biopharma

Newsletter, Press releases

This groundbreaking study introduces an entirely new approach to managing recurrent urinary tract infections. Instead of killing the bacteria, the tre...

Feb

2026

PRESS RELEASE – Lund, February 11th, 2026 – Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it’s Q2 report

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma invites you to our February investors’ meeting to be held on the 13th of February 2026, at 12:00. Please click on the link below to p...

Feb

2026

PRESS RELEASE – Lund, February 3rd, 2026 – Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma has signed an agreement with the Korean biotech company ImmunoForge, to develop novel administration technology for the peptide drug ...

Jan

2026

PRESS RELEASE – Lund 27 January 2026 – 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿

Hamlet Biopharma

Newsletter, Press releases

We warmly welcome you to the Symposium on “𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿.” The invited speakers are leading international scientists with...